Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2019³â Á¦36Â÷ Workshop °³ÃÖ
"ÇÏ´Ã, ¹Ù¶÷, º°, ±×¸®°í ½Å¾àÀÇ ²Þ"
2019³â 10¿ù 24ÀÏ(¸ñ) ~ 25ÀÏ(±Ý) / Èִнº Á¦ÁÖ ¾ÆÀÏ·£µå º¼·ë (¿À·»Áöµ¿ 2F)
1. ±Í»çÀÇ ¹«±ÃÇÑ ¹ßÀü°ú ±ÍÇÏÀÇ °Ç½ÂÇϽÉÀ» ±â¿øÇÕ´Ï´Ù.
2. Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸¿¡¼´Â Á¦36Â÷ ¿öÅ©¼¥À» ¡°ÇÏ´Ã, ¹Ù¶÷, º°, ±×¸®°í ½Å¾àÀÇ ²Þ"À̶ó´Â ÁÖÁ¦·Î ´ÙÀ½°ú °°ÀÌ °³ÃÖÇÏ¿À´Ï, ȸ¿ø ¿©·¯ºÐÀÇ ¸¹Àº Âü¿© ¹Ù¶ø´Ï´Ù. |
¡á Çà»ç°³¿ä
Çà»ç¸í |
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2019³â Á¦36Â÷ Workshop |
ÁÖÁ¦ |
ÇÏ´Ã, ¹Ù¶÷, º°, ±×¸®°í ½Å¾àÀÇ ²Þ |
ÀϽà |
2019³â 10¿ù 24ÀÏ(¸ñ) 12:00 ~ 25ÀÏ(±Ý) 15:00 |
Àå¼Ò |
Èִнº Á¦ÁÖ ¾ÆÀÏ·£µå º¼·ë (¿À·»Áöµ¿ 2F) ÀÚ¼¼È÷ º¸±â
ÁÖ¼Ò : Á¦ÁÖÆ¯º°ÀÚÄ¡µµ ¼±ÍÆ÷½Ã ¼º»êÀ¾ ¼·ÁöÄÚÁö·Î 107 Èִнº Á¦ÁÖ
|
»çÀüµî·Ï |
2019³â 9¿ù 10ÀÏ (È) ~ 10¿ù 16ÀÏ (¼ö) |
»çÀüµî·Ï±â°£ |
2019³â 9¿ù 10ÀÏ (È) ~ 10¿ù 16ÀÏ (¼ö)
1) ȨÆäÀÌÁö (www.nonclinical.or.kr)³» Á¦36Â÷ ¿öÅ©¼¥ »çÀüµî·Ï ¸Þ´º ÀÌ¿ë
2) ºñȸ¿øÀº ȸ¿ø°¡ÀÔ ÈÄ µî·Ï °¡´É
|
µî·Ïºñ |
»çÀüµî·Ï 15¸¸¿ø(Çлý 10¸¸¿ø), ÇöÀåµî·Ï 15¸¸¿ø(¼÷¹Ú Á¦°ø ºÒ°¡)
1) »çÀüµî·Ï ¹× ÇöÀåµî·Ï Ä«µå°áÁ¦ °¡´É (Ä«µå°áÁ¦ ½Ã ¼¼±Ý°è»ê¼ ¹ßÇàºÒ°¡)
2) ÀÚ·áÁý, ¼ö·áÁõ, ¼÷¹Ú (4ÀÎ/1½Ç), 24ÀÏ Áᫎ ¹× ¼®½Ä, 25ÀÏ Á¶½Ä ¹× Áᫎ Æ÷ÇÔ
3) ¼¼±Ý°è»ê¼ ¹ß±Þ (ÀÔ±ÝÀÏ ±âÁØ 1ȸ ¹ß±Þ)ÀÌ ÇÊ¿äÇϽŠºÐÀº »ç¾÷ÀÚµî·ÏÁõ ÷ºÎ ¿ä¸Á
4) ÇöÀåµî·ÏÀÇ °æ¿ì, ¼¼±Ý°è»ê¼ ¹ß±Þ ºÒ°¡, ¿¬±¸È¸ ÀÚü ¿µ¼öÁõ ¹ß±Þ
5) ÀԱݰèÁ : ¿ì¸®ÀºÇà 1005-403-436526 ¢ßµå¸²ÆÄÆ®³Ê Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸
6) ÀԱݸ¶°¨ : 2019³â 10¿ù 18ÀÏ(±Ý), ÀÔ±Ý ½Ã ¼Ò¼Ó, ¼º¸í ±âÀÔ ¿ä¸Á |
¹®ÀÇ |
±âŸ ¹®ÀÇ»çÇ×Àº Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ »ç¹«±¹À¸·Î ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
KSNS »ç¹«±¹ : Tel. 031-702-9123 / E-mail. ksns@nonclinical.or.kr / ´ã´çÀÚ. ±èÁذï
|
º°Ã· |
[°ø¹®] KSNS 36Â÷ ¿öÅ©¼¥ °³ÃÖ ¾È³»
º¸°Ç»ê¾÷ÁøÈï¿ø ±â¾÷È«º¸ ¸®Ç÷¿
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ ±â¼úºñÁî´Ï½º Çù·Â °øµ¿ ½ÉÆ÷Áö¿ò °èȹ¾È
|
¡á µî·Ï¾È³»
- »çÀüµî·Ï ¾È³»
µî·Ï±â°£ |
2019³â 9¿ù 10ÀÏ (È) ~ 10¿ù 16ÀÏ (¼ö) |
µî·Ï¹æ¹ý |
- ¿¬±¸È¸ ȨÆäÀÌÁö (www.nonclinical.or.kr) ÇмúÇà»ç >»çÀüµî·Ï ¸Þ´º ÀÌ¿ë
- ºñȸ¿øÀº ȸ¿ø°¡ÀÔ ÈÄ, »çÀüµî·ÏÀÌ °¡´ÉÇÕ´Ï´Ù.
|
- µî·Ïºñ <Áß¿ä°øÁö >Ä«µå°áÁ¦ °¡´É
µî·Ïºñ ±¸ºÐ |
»çÀüµî·Ï |
ÇöÀåµî·Ï |
Á¤È¸¿ø |
150,000¿ø |
150,000¿ø |
Çлýȸ¿ø |
100,000¿ø |
100,000¿ø |
• »çÀüµî·Ïºñ : ÀÚ·áÁý, ¼ö·áÁõ, ¼÷¹Ú (4ÀÎ/1½Ç), 24ÀÏ Áᫎ ¹× ¼®½Ä, 25ÀÏ Á¶½Ä ¹× Áᫎ Æ÷ÇÔ
• ¼¼±Ý°è»ê¼ ¹ß±Þ(ÀÔ±ÝÀÏ ±âÁØ 1ȸ ¹ß±Þ)ÀÌ ÇÊ¿äÇÒ °æ¿ì, ¿Â¶óÀÎ µî·Ï¶§ ¼¼±Ý°è»ê¼ ¹ßÇàÇà¿©ºÎ¸¦ üũÇϰí, »ç¾÷ÀÚµî·ÏÁõ »çº»À» ¹Ýµå½Ã ÷ºÎ
• ÇöÀåµî·Ï ¹× Çлýµî·ÏÀÇ °æ¿ì, ¼¼±Ý°è»ê¼ ¹ß±Þ ºÒ°¡, ¿¬±¸È¸ ÀÚü ¿µ¼öÁõ ¹ß±Þ |
- ¹«ÅëÀåÀÔ±Ý (°èÁÂÀÌü)
ÀԱݰèÁ |
¿ì¸®ÀºÇà 1005-403-436526 ¢ßµå¸²ÆÄÆ®³Ê Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ |
ÀԱݸ¶°¨ |
~ 2019³â 10¿ù 18ÀÏ (±Ý) 18½Ã ±îÁö |
• ÀԱݽà ¹Ýµå½Ã "¼Ò¼Ó/¼º¸í" À» ±âÀÔÇϼ¼¿ä.
• ¹«ÅëÀå ÀÔ±Ý(°èÁÂÀÌü)ÀÌü ÈÄ, »ç¹«±¹¿¡¼ ÀÔ±ÝÀ» È®ÀÎÇÏ´Â ½Ã°£ÀÌ ÇÊ¿ä ÇÕ´Ï´Ù.
• ±âŸ µî·Ï °ü·Ã ¹®ÀÇ»çÇ×Àº Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ »ç¹«±¹À¸·Î ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
TEL. 031-702-9123 / E-mail. ksns@nonclinical.or.kr, ±èÁذï
|
¡á ÇÁ·Î±×·¥ ¾È³»
- ÀϽà : 2019³â 10¿ù 24ÀÏ(¸ñ) 12:00 ~ 25ÀÏ(±Ý) 15:00
- Àå¼Ò : Èִнº Á¦ÁÖ ¾ÆÀÏ·£µå º¼·ë (¿À·»Áöµ¿ 2F)
- ÁÖÁ¦ : ÇÏ´Ã, ¹Ù¶÷, º°, ±×¸®°í ½Å¾àÀÇ ²Þ
|
Day 1 |
10¿ù 24ÀÏ (¸ñ) |
½Ã°£ |
ÇÁ·Î±×·¥ |
12:00~12:50 |
µî·Ï ¹× Á¡½Ä ½Ä»ç |
12:50~13:00 |
°³È¸»ç (¿À¼¼¿õ ȸÀå) |
13:00~13:10 |
Ãà»ç (½ÄǰÀǾàǰ¾ÈÀüÆò°¡¿øÀå À̵¿Èñ) |
Session 1 |
Plenary talk |
13:10~13:50 |
ÀÓ»óÀû °üÁ¡¿¡¼ ¹Ù¶óº¸´Â ºñÀӻ󿬱¸ Àü·« (¿¬¼¼ÀÇ·á¿ø, ½ÉÀç¿ë) |
Session 2 |
Platform |
13:50~14:30 |
¾Ï´Ü¹éÀ¯Àüü ºÐ¼®À» ÅëÇÑ ÀÌÇ༺¿¬±¸ ¹æÇâ (±¹¸³¾Ï¼¾ÅÍ, ¹ÚÁ¾¹è) |
14:30~15:10 |
AI-powered drug discovery and development (GIST, ³²È£Á¤) |
15:10~15:30 |
Booth exhibition & Coffee break |
Session 3 |
Case study 1 |
15:30~16:10 |
BBT-877 ºñÀÓ»ó/ÀÓ»ó°³¹ß ¹× ¶óÀ̼¾½Ì (ºê¸´Áö¹ÙÀÌ¿À, ÀÌÁ¤±Ô) |
16:10~16:50 |
³Ä¡¼º ¶Ç´Â °íÀ§Çè °¨¿°º´ ¿¹¹æ ¹é½ÅÀ¸·Î¼ DNA¹é½ÅÀÇ ¿ªÇÒ ¹× ºñÀÓ»ó/ÀÓ»ó ¿¬±¸°³¹ß »ç·Ê (Áø¿ø»ý¸í°úÇÐ, Á¤¹®¼·) |
16:50~17:40 |
DWN12088, A Novel First-In-Class PRS Inhibitor for the Treatment of Fibrotic Diseases (´ë¿õÁ¦¾à, ¹ÚÁؼ®) |
18:40~21:00 |
Dinner seminar(¿ì½Ã¾ÛÅØ/Å¥º£½ºÆ® ¹ÙÀÌ¿À) & Social networking |
Day 2 |
10¿ù 25ÀÏ (±Ý) |
½Ã°£ |
ÇÁ·Î±×·¥ |
07:00~09:30 |
¾ÆÄ§ ½Ä»ç |
Session 4 |
¾àÈ¿ºÐ°ú |
µ¶¼ººÐ°ú |
¾àµ¿ºÐ°ú |
09:40~10:20 |
The current trend of allosteric SHP2 inhibitor in cancer
(SK¹ÙÀÌ¿ÀÆÊ, ±è³²ÈÆ) |
US FDA SEND µµÀÔ¿¡ µû¸¥ ±¹³» ºñÀÓ»ó½ÃÇè±â°üÀÇ ´ëÀÀ°ú ³ª¾Æ°¥ ¹æÇâ
(KIT, Á¤ÁöÈÆ) |
In vitro investigation of the inhibitor preincubation effect on multiple classes of clinically relevant transporters
(SOLVO, Beáta Marianna Kovács) |
10:20~10:40 |
Booth exhibition & Coffee break |
10:40~11:20 |
±Û·Î¹ú ÀÓ»ó3»ó ÅëÁõ Ä¡·áÁ¦ Opiranserin °³¹ß »ç·Ê ¼Ò°³
(ºñº¸Á¸, ÀÌÇÑÁÖ) |
ÀÓ»ó½ÃÇè°ËüºÐ¼®ÀÇ GLPÀû¿ë
(°Ç¾ç´ë, ȲÁø¾Æ) |
Time-dependent Inhibitor¿Í Reactive Metabolite, ¹«¾ùÀÌ ´Ù¸¥°¡?
(LGÈÇÐ, À̽ÂÇÐ) |
11:20~11:40 |
Effect of intravitreal administration of ranibizumab inspontaneously dysmetabolic non-human primate
(Sichuan Primed Shines Biotech, Li Gong) |
Challenges with Immunogenicity Assay Design to Support Gene Therapy Programs
(Charles River Lab., Jessica St. Charles) |
Role and Consideration of Toxicokinetic study in preclinical study
(KIT, ÀÌÁ¾È) |
11:40~12:00 |
Novel strategies to optimize animal models of human nonalcoholic steatohepatitis for drug development
(Physiogenex, François Briand) |
|
|
12:00~13:30 |
Luncheon seminar(DT & CRO) & Booth exhibition |
Session 5 |
Case study 2 |
13:30~14:10 |
ÃֽŠFDA ½Å¾à½ÂÀÎ »ç·Ê ¼Ò°³ (SK¹ÙÀÌ¿ÀÆÊ, ¹ÚÁ¤½Å) |
14:10~14:50 |
YH25724, a novel long-acting dual agonist for the treatment of nonalcoholic steatohepatitis (NASH) (À¯ÇѾçÇà, ±èÁØÈ¯) |
14:50~15:00 |
Æóȸ»ç ¹× °æÇ° Ãß÷ (ºÎȸÀå, ½ÉÇöÁÖ) |
¡Ý °øµ¿½ÉÆ÷Áö¿ò
Session 6 |
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸/Çѱ¹º¸°Ç»ê¾÷ÁøÈï¿ø º¸°ÇÀÇ·á »êÇп¬º´ ±â¼ú-ºñÁî´Ï½º Çù·Â °øµ¿½ÉÆ÷Áö¿ò |
Day 1 |
10¿ù 24ÀÏ (¸ñ) |
½Ã°£ |
ÇÁ·Î±×·¥ |
~13:40 |
µî·Ï |
13:40~14:00 |
½Å°æÁ¤½ÅÁúȯ Ä¡·áÁ¦ ¾àÈ¿Æò°¡ Ç÷§Æû ±â¼ú |
(ÁÖ)´º·Îºñ½º |
14:00~14:20 |
´ë»çÈ¿¼Ò/¼ö¼Ûü ±â¹ÝÀÇ in vitro ADME ºÐ¼®±â¼ú ¹× ¾à¹°À¯ÀüÀÚ ºÐ¼®±â¼ú |
(ÁÖ)¿¡½ºÇǸ޵å |
14:20~14:40 |
°íÇ÷¾Ð °³¼±À» À§ÇÑ »êÈÁú¼Ò(NO)ÃËÁø À½·á |
(ÁÖ)¹è·Á |
14:40~15:00 |
Coffee break |
15:00~18:00 |
º¸°ÇÀÇ·á TLO ¿¬±¸ÀÚ ¹× ±â¾÷ °£ 1:! ±â¼ú ºñÁî´Ï½ºÆÄÆ®³Ê¸µ |
¿¬±¸ÀÚ ¹× À¯¸Á/Á¦¾à±â¾÷ |
* »ó±â ÇÁ·Î±×·¥Àº ¿¬ÀÚ ¹× ±âŸ »çÁ¤À¸·Î º¯µ¿ ¼ö ÀÖ½À´Ï´Ù.
¡á ¿À½Ã´Â ±æ
ÁÖ¼Ò |
Á¦ÁÖÆ¯º°ÀÚÄ¡µµ ¼±ÍÆ÷½Ã ¼º»êÀ¾ ¼·ÁöÄÚÁö·Î 107 Èִнº Á¦ÁÖ |
ȨÆäÀÌÁö |
Èִнº Á¦ÁÖ ¾ÆÀÏ·£µå º¼·ë (¿À·»Áöµ¿ 2F) ÀÚ¼¼È÷ º¸±â
|
 |
¡á ±³Åë Æí
¡Ý ±ÞÇà¹ö½º
- 110-1 (¼Ò¿ä½Ã°£:69ºÐ) [°øÇ× ¡æ °í¼º¸® ÇÏÂ÷ ¡æ ¼º»êÆ÷Ç× ¡æ ¿©°´Å͹̳Î]
- 110-2 (¼Ò¿ä½Ã°£:85ºÐ) [°øÇ× ¡æ °í¼º¸® ÇÏÂ÷ ¡æ ¼º»êÆ÷Ç× ¡æ ¿©°´Å͹̳Î]
- °í¼º¸® ÇÏÂ÷ ÈÄ Åýà ÀÌ¿ë:°Å¸® 3.1 km / ¿ä±Ý 4õ¿ø ÀÌÇÏ
- ±ÞÇà¹ö½º ž½ÂÀå:°øÇ× 1¹ø Ãⱸ ¾Õ
¡Ý °øÇ× ¹«·á ¼ÅƲ
• °øÇ× ¡æ Èִнº Á¦ÁÖ (10¿ù 24ÀÏ)
±¸ºÐ |
1ȸÂ÷ |
Ãß°¡1* |
Ãß°¡2* |
Ãß°¡3* |
2ȸÂ÷ |
Ãß°¡4* |
3ȸÂ÷ |
4ȸÂ÷ |
5ȸÂ÷ |
Ãâ¹ß½Ã°£ |
10:00 |
10:30 |
11:00 |
11:30 |
12:00 |
12:30 |
14:00 |
16:00 |
19:10 |
µµÂø½Ã°£ |
11:10 |
11:40 |
12:10 |
12:40 |
13:10 |
13:40 |
15:10 |
17:10 |
20:20 |
ž½ÂÀå¼Ò |
Á¦ÁÖ°øÇ× C-Zone (9, 10, 11¹ø) ÁÖÂ÷Àå |
* ¿öÅ©¼¥ Âü¼®ÀÚ¸¦ À§ÇÑ Ãß°¡ ¼ÅƲ Â÷·®
• Èִнº Á¦ÁÖ ¡æ °øÇ× (10¿ù 25ÀÏ)
±¸ºÐ |
1ȸÂ÷ |
2ȸÂ÷ |
3ȸÂ÷ |
4ȸÂ÷ |
Ãß°¡1~4* |
5ȸÂ÷ |
Ãâ¹ß½Ã°£ |
- |
10:30 |
12:30 |
14:30 |
15:00~16:00 |
17:30 |
µµÂø½Ã°£ |
- |
11:40 |
12:40 |
15:40 |
16:10~17:10 |
19:00 |
ž½ÂÀå¼Ò |
¿À·»Áöµ¿ Çö°ü ¾Õ |
* ¿öÅ©¼¥ Âü¼®ÀÚ¸¦ À§ÇÑ Ãß°¡ ¼ÅƲ Â÷·®, ÇÁ·Î±×·¥ Á¾·á ÈÄ ¹Ù·Î ½ÂÂ÷Çϰí Ãâ¹ß ¿¹Á¤
** µµÂø½Ã°£Àº µµ·Î ±³Åë »óȲ¿¡ µû¶ó ´Ù¼Ò Áö¿¬µÉ ¼ö ÀÖ½À´Ï´Ù. ¾çÇØºÎʵ右´Ï´Ù.
|